The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world.
During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML.
When:
Wednesday, November 6 from 5–8 PM at the Radisson Blu Hotel, adjacent to the AORTIC conference center in Maputo, Mozambique.
Discussion Topics:
In this session leading physicians and experts will discuss the following:
Get to know the speakers:
This is an opportunity to join in-person to learn from the experts and exchange valuable ideas and transformative practices. Light dinner refreshments will be served.
To reserve your place please email Arlene Harris-Buchan.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).
We are delighted to announce that Bryan Murphy-Eustis, MBA, MPH, is joining The Max Foundation’s Executive Team as Vice President of Programs. Bryan joins the team with more than 18 years of experience building and leading high-impact mission-driven teams, most recently as Commercialization Lead for Medical Technologies at Global Good at Intellectual Ventures. Previously he….
Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.
